<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance use and addiction treatment</journal-title></journal-title-group><issn pub-type="ppub">2949-8767</issn><issn pub-type="epub">2949-8759</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10044504</article-id><article-id pub-id-type="pmcid-ver">PMC10044504.1</article-id><article-id pub-id-type="pmcaid">10044504</article-id><article-id pub-id-type="pmcaiid">10044504</article-id><article-id pub-id-type="manuscript-id">NIHMS1873802</article-id><article-id pub-id-type="pmid">36804351</article-id><article-id pub-id-type="doi">10.1016/j.josat.2023.208973</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1873802</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1873802</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Trajectories of non&#8211;prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Daniulaityte</surname><given-names initials="R">Raminta</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nahhas</surname><given-names initials="RW">Ramzi W.</given-names></name><degrees>Ph.D.</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silverstein</surname><given-names initials="S">Sydney</given-names></name><degrees>Ph.D.</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martins</surname><given-names initials="S">Silvia</given-names></name><degrees>Ph.D.</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carlson</surname><given-names initials="RG">Robert G.</given-names></name><degrees>Ph.D.</degrees><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>College of Health Solutions, Arizona State University, Phoenix, Arizona</aff><aff id="A2"><label>2</label>Department of Population and Public Health Sciences, Boonshoft School of Medicine, Wright State University</aff><aff id="A3"><label>3</label>Department of Psychiatry, Boonshoft School of Medicine, Wright State University</aff><aff id="A4"><label>4</label>Department of Epidemiology Columbia University Mailman School of Public Health</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1"><bold>Contributors.</bold> R. Daniulaityte, R. Nahhas, S. Martins, and R. Carlson designed the study. R. Daniulaityte reviewed the literature and wrote the first draft of the paper. R. Nahhas conducted statistical analyses. S. Silverstein, A. Moeller and A. Zaragozar contributed to data collection and refinement of conceptual design. S. Martins contributed to the analytical approach. All authors reviewed, commented, and edited the manuscript. All authors contributed to and have approved the final manuscript.</p></fn><corresp id="CR1">Corresponding Author: Raminta Daniulaityte, PhD, 425 N 5th Street, Arizona Biomedical Collaborative, Room 121, Arizona State University, College of Health Solutions, Phoenix, AZ 85004, <email>raminta.daniulaityte@asu.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2023</year></pub-date><volume>147</volume><issue-id pub-id-type="pmc-issue-id">432121</issue-id><fpage>208973</fpage><lpage>208973</lpage><pub-history><event event-type="nihms-submitted"><date><day>22</day><month>02</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1873802.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction</title><p id="P2">With the increasing use of non&#8211;prescribed buprenorphine (NPB), we need more data to identify the longitudinal patterns of NPB use. The goal of this natural history study is to characterize heterogeneity in trajectories of NPB, other opioid use, and participation in medication for opioid disorder (MOUD) treatment among a community-recruited sample of individuals with current opioid use disorder (OUD).</p></sec><sec id="S2"><title>Methods</title><p id="P3">The study recruited a community-based sample of 357 individuals with OUD who used NPB in the past 6-months in Ohio, United States, for baseline and follow-up assessments (every 6 months for 2 years) of drug use, treatment participation, and other health and psychosocial characteristics. The study used multiple imputation to handle missing data. We used a multi-trajectory latent class growth analysis (MT-LCGA) to find salient groupings of participants based on the trajectories of NPB, other opioid use, and treatment participation.</p></sec><sec id="S3"><title>Results</title><p id="P4">Over time, NPB use frequency declined from a mean of 14.6% of days at baseline to 3.6% of days at 24-month follow-up along with declines in heroin/fentanyl (56.4% to 23.6% of days) and non&#8211;prescribed pharmaceutical opioid (NPPO) use (11.6% to 1.5% of days). Participation in MOUD treatment increased from a mean of 17.0% of days at baseline to 52.4% of days at 24-months. MT-LCGA identified a 6-class model. All six classes showed declines in NPB use. Class 1 (28%) was characterized by high and increasing MOUD treatment utilization. Class 2 (21%) showed sustained high levels of heroin/fentanyl use and had the lowest levels of NPB use (2.2% of days) at baseline. Class 3 (3%) was characterized as the primary NPPO use group. Class 4 (5%) transitioned from high levels of NPB use to increased MOUD treatment utilization. It had the highest levels of NPB use at baseline (average of 80.7% of days) that decreased to an average of 12.9% of days at 24-months. Class 5 (16%) showed transition from high levels of heroin/fentanyl use to increased MOUD treatment utilization. Class 6 (27%) showed decreased heroin/fentanyl use over time and low MOUD treatment utilization. Classes showed varying levels of improvement in psychosocial functioning, polydrug use, and overdose risks.</p></sec><sec id="S4"><title>Conclusion</title><p id="P5">Overall, our findings suggest that NPB use was generally self-limiting with individuals reducing their use over time as some engage in greater utilization of MOUD treatment. A need exists for continuing improvements in MOUD treatment access and retention.</p></sec></abstract><kwd-group><kwd>Buprenorphine</kwd><kwd>Heroin</kwd><kwd>Fentanyl</kwd><kwd>Non&#8211;prescribed pharmaceutical opioids</kwd><kwd>Opioid use disorder</kwd><kwd>Longitudinal study</kwd><kwd>Latent class growth analysis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>